Mylan launches first generic Xopenex "at risk" in US
04 September 2009
Nancy Faigen
Please Login to read the full article.
04 September 2009
Nancy Faigen
nancy.faigen@informausa.com
Mylan Laboratories's Dey subsidiary has launched levalbuterol inhalation solution 0.25% (1.25mg/0.5mL), the first generic version of Sepracor's short-acting beta-agonist Xopenex, "at risk" in the US as patent litigation with the innovator continues.
The generic has 180 days of marketing...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sandoz wants Novo's sole US Prandin patent ruled invalid in a long running case
- Sun set for generic Uroxatral ER launch in US with 180-day exclusivity
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
- Glenmark settles with Genzyme and Daiichi Sankyo over US Welchol generics
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
